The estimated Net Worth of Patrick Taylor Horn is at least $1.68 Milione dollars as of 22 October 2021. Patrick Horn owns over 95 units of Albireo Pharma Inc stock worth over $545,473 and over the last 12 years he sold ALBO stock worth over $27,211. In addition, he makes $1,108,730 as Chief Medical Officer at Albireo Pharma Inc.
Patrick has made over 14 trades of the Albireo Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 95 units of ALBO stock worth $2,739 on 22 October 2021.
The largest trade he's ever made was exercising 10,000 units of Albireo Pharma Inc stock on 13 June 2017 worth over $20,300. On average, Patrick trades about 3,087 units every 102 days since 2013. As of 22 October 2021 he still owns at least 12,355 units of Albireo Pharma Inc stock.
You can see the complete history of Patrick Horn stock trades at the bottom of the page.
Dr. Patrick T. Horn M.D. Ph.D. serves as Chief Medical Officer of the Company. He previously served as Senior Vice President, Medical and Clinical Development at Orphan Technologies Ltd., a biopharmaceutical company, from January 2018 to July 2018. Prior to that, he served as Chief Medical Officer at Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, from January 2011 to December 2017. Prior to that, he served as Vice President, Clinical & Medical Affairs at Dyax Corporation, a biopharmaceutical company, from September 2007 to December 2010. Previously, Dr. Horn served in various positions at Abbott Laboratories, a pharmaceutical company, from 2001 to 2006, most recently serving as Medical Director, Head of Clinical Pharmacology. Dr. Horn received a B.S. in Chemistry from the University of Illinois, a Ph.D. in the Pharmacological and Physiological Sciences from the University of Chicago and an M.D. from the University of Chicago, Pritzker School of Medicine.
As the Chief Medical Officer of Albireo Pharma Inc, the total compensation of Patrick Horn at Albireo Pharma Inc is $1,108,730. There are 5 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.
Patrick Horn is 65, he's been the Chief Medical Officer of Albireo Pharma Inc since 2018. There are 5 older and 15 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
Patrick's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs e Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Inc executives and other stock owners filed with the SEC include: